Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Seroquel Patent Expiration Leads To Sharp 2Q Revenue Decline For AstraZeneca

This article was originally published in The Pink Sheet Daily

Executive Summary

With U.S. revenues down 29% and the EU take off by 20%, perhaps AstraZeneca’s greatest concern is only 1% revenue growth in emerging markets, which the pharma has targeted as a key revenue-driver through its patent cliff.

You may also be interested in...

A Closer Look: Is Double-Digit Growth Sustainable In Emerging Markets? (Part 2 of 2)

A new debate among investors concerns whether double-digit growth is possible across emerging markets or only in China. PharmAsia News takes a closer look.

Brennan’s Departure Not Expected To Disrupt Current Business Development Strategy At AstraZeneca

With the longtime CEO stepping down as of June 1, his successor will assume the challenge of handling generic challengers to several mature blockbuster products and the slow launch of Brilinta. The current business-development strategy, as reflected in a recent partnership and acquisition, is expected to stay in place for now.

Brennan’s Abrupt Departure Has Some Viewing AstraZeneca As A Buyout Target

A rough first quarter and news of the CEO’s decision to step down in slightly over a month leads to speculation that AstraZeneca could be an attractive M&A target for another pharma that might shut down the company’s struggling R&D effort and cash in on the existing portfolio.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts